What ARA-290 is

ARA-290 (cibinetide) is an 11-amino-acid peptide copied from one surface of erythropoietin. EPO's helix B face points away from the red-blood-cell receptor and instead contacts a repair receptor; ARA-290 reproduces that surface, activating the repair receptor while not touching the blood-making one. The result delivers EPO's protective effect without blood thickening, thrombosis risk, or hemoglobin monitoring.

How ARA-290 works

It acts only where there is damage

ARA-290 works through the innate repair receptor (a complex of the EPO receptor and CD131). This receptor is largely absent in healthy tissue and appears in response to injury, inflammation, or metabolic stress — so the drug has something to act on only where tissue is already hurt. Binding triggers JAK2/STAT and PI3K/Akt signaling with reduced NF-κB activity, calming inflammation and supporting cell survival and repair. It works on the underlying nerve damage rather than masking the pain signal.

Receptor dependence is well proven

In a rat nerve-injury study, ARA-290 relieved touch and cold hypersensitivity, and the effect disappeared entirely in mice bred without CD131. The same receptor dependence was shown in stroke and colitis models — three independent studies, three organ systems, same answer.

Why it does not make red blood cells

EPO's blood-making effect requires a different receptor arrangement that ARA-290 does not engage. In human trials, hemoglobin, hematocrit, and platelet counts did not change, and no anti-drug antibodies were detected.

The short-half-life paradox

ARA-290 clears fast (~2 min IV, ~20 min subcutaneous), yet effects last days to months. The receptor acts like a switch: the drug flips it on and clears, and the cell keeps running the repair program — benefit was still measurable nine months after the last dose in the sarcoidosis trial.

What the human trials found

The often-quoted "23% increase" is in GAP-43-positive regenerating fibers from skin biopsy at 4 mg — a regeneration signal, not corneal nerve fiber area. Standard intraepidermal nerve fiber density did not change, and between-group pain did not reach significance (p=0.157). The structural-regeneration and symptom-score signals were real; the pain-score signal was not clean.

Who ARA-290 may help, and who it will not

Good fit: burning, tingling, electric or shooting pain; skin hypersensitive to light touch (allodynia); symptoms following a nerve territory; numbness or temperature/sweating changes.

Poor fit: deep ache or stiffness that tracks with load and rest; swelling, warmth, redness; pure weakness without sensory symptoms; ongoing structural damage on imaging. For those, a structural-repair approach such as BPC-157 and TB-500 is a better start. For post-surgical nerve pain, the rationale is preclinical (an animal surgical-nerve-injury study); no human trial has tested it.

Dosing

Higher is not better: 8 mg added nothing over 4 mg; 1 mg was below the useful range. An IV alternative (2 mg 3×/week for 4 weeks) gave comparable outcomes but needs a clinical setting. Reconstitute with bacteriostatic water (isotonic diluent reduces sting); inject in its own syringe. See the reconstitution calculator. No approved product exists — access is via research-peptide suppliers of variable quality.

What to expect over a course

• Weeks 1–2: burning and tingling may begin to settle.

• Weeks 2–4: most measured symptom change in trials occurred by the end of the 4-week course.

• After stopping: benefit persisted for months; nerve-fiber measures kept improving after dosing stopped.

Used as a defined course (4–12 weeks), not ongoing therapy. A repeat course is reasonable if symptoms return after several months.

Side effects and safety

Well tolerated across Phase 2 trials, with side-effect rates similar to placebo. Common: mild injection-site reactions, transient headache, fatigue. Core advantage: no clinically significant change in hemoglobin, hematocrit, or platelets, and no anti-drug antibodies. Limits: total human exposure is small and short (12 weeks longest, in 8 people); the diabetic trial had one possibly-related kidney-function worsening and one fatal heart attack judged unrelated; the 8 mg arm had one case of suicidal ideation. No chronic-use data — a reassuring safety signal, not established long-term safety.